(Total Views: 90)
Posted On: 09/19/2025 3:48:49 PM
Post# of 61
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline
Oncotelic Therapeutics (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth.” The release highlights the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy and nanomedicine. Dr. Trieu previously developed Abraxane(R), a nanotechnology-based formulation that transformed treatment for breast, lung and pancreatic cancers, and advanced Cynviloq(TM), a novel micellar paclitaxel therapy. The feature underscores how his track record and expertise position Oncotelic to advance pioneering therapies with strong market potential.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth.” The release highlights the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy and nanomedicine. Dr. Trieu previously developed Abraxane(R), a nanotechnology-based formulation that transformed treatment for breast, lung and pancreatic cancers, and advanced Cynviloq(TM), a novel micellar paclitaxel therapy. The feature underscores how his track record and expertise position Oncotelic to advance pioneering therapies with strong market potential.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
